Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
N-glycosylation by Mgat5 imposes a targetable constraint on immune-mediated tumor clearance
Erin E. Hollander, Rosemary E. Flock, Jayne C. McDevitt, William P. Vostrejs, Sydney L. Campbell, Margo I. Orlen, Samantha B. Kemp, Benjamin M. Kahn, Kathryn E. Wellen, Il-Kyu Kim, Ben Z. Stanger
Erin E. Hollander, Rosemary E. Flock, Jayne C. McDevitt, William P. Vostrejs, Sydney L. Campbell, Margo I. Orlen, Samantha B. Kemp, Benjamin M. Kahn, Kathryn E. Wellen, Il-Kyu Kim, Ben Z. Stanger
View: Text | PDF
Research Article Cell biology Oncology

N-glycosylation by Mgat5 imposes a targetable constraint on immune-mediated tumor clearance

  • Text
  • PDF
Abstract

The regulated glycosylation of the proteome has widespread effects on biological processes that cancer cells can exploit. Expression of N-acetylglucosaminyltransferase V (encoded by Mgat5 or GnT-V), which catalyzes the addition of β1,6-linked N-acetylglucosamine to form complex N-glycans, has been linked to tumor growth and metastasis across tumor types. Using a panel of murine pancreatic ductal adenocarcinoma (PDAC) clonal cell lines that recapitulate the immune heterogeneity of PDAC, we found that Mgat5 is required for tumor growth in vivo but not in vitro. Loss of Mgat5 results in tumor clearance that is dependent on T cells and dendritic cells, with NK cells playing an early role. Analysis of extrinsic cell death pathways revealed Mgat5-deficient cells have increased sensitivity to cell death mediated by the TNF superfamily, a property that was shared with other non-PDAC Mgat5-deficient cell lines. Finally, Mgat5 knockout in an immunotherapy-resistant PDAC line significantly decreased tumor growth and increased survival upon immune checkpoint blockade. These findings demonstrate a role for N-glycosylation in regulating the sensitivity of cancer cells to T cell killing through classical cell death pathways.

Authors

Erin E. Hollander, Rosemary E. Flock, Jayne C. McDevitt, William P. Vostrejs, Sydney L. Campbell, Margo I. Orlen, Samantha B. Kemp, Benjamin M. Kahn, Kathryn E. Wellen, Il-Kyu Kim, Ben Z. Stanger

×

Figure 1

Mgat5 loss sensitizes cancer cells to immune clearance.

Options: View larger image (or click on image) Download as PowerPoint

Mgat5 loss sensitizes cancer cells to immune clearance.
(A) Mgat5 expre...
(A) Mgat5 expression in human pancreatic cancer (left, n = 179) and normal pancreas (right, n = 171) from GEPIA2. In the box-and-whisker plot, the lower and upper bounds of the box represent the 25th and 75th percentiles of the data, respectively, with the line within the box set at the median. Whiskers are set at the lowest and greatest values in the data set, excluding the outliers plotted beyond the whiskers. (B) Histogram of PHA-L binding to 2838c3 EV and Mgat5-KO cell lines. (C) Relative growth of T cell–inflamed (2838c3) EV and Mgat5-KO cell lines in vitro. Statistical analysis done using 2-way ANOVA with n = 3 replicates per data point. (D) Growth (mm3) of 2838c3 EV (n = 6), Mgat5-KO-A (n = 7), and Mgat5-KO-B (n = 7) subcutaneous tumors in C57BL/6 mice over time. Statistical analysis done using 2-way ANOVA for this and all following tumor growth curves. Data representative of 2 independent experiments. (E) Tumor weights in T cell–inflamed (2838c3) WT (n = 4) and Mgat5-KO-A (n = 4) cells implanted orthotopically into mouse pancreas. Data represent mean ± SEM. Statistical analysis using unpaired, 2-tailed Student’s t test. (F) Quantification of immunofluorescent staining for PHA-L, CD8+ T cells, granzyme B (GZMB), FOXP3, aSMA, and cleaved caspase 3 (CC3) by percentage area per high-power field (HPF) using ImageJ. Three mice per condition (EV, KO) with 3–5 HPF per tumor. Statistics using unpaired, 2-tailed Student’s t test. (G) Growth (mm3) and weights (mg) of 2838c3 EV (n = 8) and Mgat5-KO-A (n = 10) subcutaneous tumors in NOD/SCID mice. Data represent mean ± SEM. (H) Growth (mm3, left) of 6694c2 EV (n = 8), Mgat5-KO-A (n = 10), and Mgat5-KO-B (n = 10) subcutaneous tumors in C57BL/6 mice. Data represent mean ± SEM. (I) Subcutaneous tumor growth over time of 6419c5 EV (n = 6) and Mgat5-KO (n = 6) tumors in C57BL/6 mice. Data representative of 2 independent experiments. Data represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts